• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Evolent Health Names Kim Keck To Board of Directors

    1/13/21 7:00:00 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary
    Get the next $EVH alert in real time by email

    WASHINGTON, Jan. 13, 2021 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced that Kim A. Keck has been appointed to its Board of Directors, effective immediately and will stand for election at the Company's 2021 annual meeting of stockholders. Ms. Keck has more than 30 years' experience in the health care industry and currently serves as President and Chief Executive Officer of the Blue Cross Blue Shield Association (BCBSA), a national federation of 36 independent, community-based and locally operated Blue Cross and Blue Shield companies that provide health care coverage for one in three Americans. Ms. Keck will fill the seat vacated by Bruce Felt, who has decided to retire from the Board effective January 11, 2021. As part of the Board's succession plan, independent director Cheryl Scott will serve as Lead Independent Director following Mr. Felt's retirement.

    "Kim is a highly respected leader in the health care industry and we are very pleased to welcome such a seasoned executive to our Board," said Evolent Health Executive Chairman and Co-Founder Frank Williams. "Our company is at an important inflection point, and we look forward to Kim's valuable perspectives and insights as we execute on our next phase of profitable growth. We also welcome Cheryl Scott into the role of Lead Independent Director.  Her independent counsel and deep industry expertise, as well as the active role she takes in engaging with all our shareholders, is key to the continued evolution of Evolent. Finally, I would like to thank Bruce Felt for his service. Bruce has been an outstanding board member and we appreciate his many significant contributions in helping guide Evolent to the strong position we are in today."

    "I am excited to join Evolent's Board to help the Company achieve its mission of transforming the way care is delivered and experienced," said Ms. Keck. "Evolent has a reputation as a valuable partner for payers and providers, which gives me confidence that it will be able to deliver on the opportunities still ahead. I look forward to working with its industry-leading team and my fellow independent directors to drive further growth in core services that address critical problems in health care."

    "Kim's deep knowledge and track record within the health insurance payer community will be instrumental as we expand our core offerings in that market," said Evolent's Chief Executive Officer and Co-Founder Seth Blackley. "We look forward to her contributions as we continue to execute our strategy to maximize shareholder value by growing our leading clinical and administrative solutions."

    Prior to becoming President and CEO of BCBSA in January 2021, Ms. Keck served as President and Chief Executive Officer of Blue Cross Blue Shield of Rhode Island since 2016.  During her leadership at BCBSRI, she advanced a vision to lead a state of health and well-being across Rhode Island, putting the Plan's 450,000 members at the center of BCBSRI's strategic initiatives around cost and value stewardship, convenience, and comprehensive health. Previously, Ms. Keck held several leadership roles at Aetna from 2001 to 2016, including Senior Vice President from 2010 to 2016.  Ms. Keck serves on the Board of Directors of Oak Street Health and the Blue Cross Blue Shield Association. She received a B.A. in Mathematics from Boston College and an MBA in Finance from the University of Connecticut, and is a Chartered Financial Analyst.

    About Evolent Health 
    Evolent Health (NYSE: EVH) delivers proven clinical and administrative solutions that improve whole-person health while making health care simpler and more affordable. Our solutions encompass total cost of care management, specialty care management, and administrative simplification. Evolent serves a national base of leading payers and providers, is the first company to receive the National Committee for Quality Assurance's Population Health Program Accreditation, and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting evolenthealth.com.

    Contacts:

    Chelsea Griffin
    Investor Relations
    919.817.8045
    [email protected]  

    Dan Paladino
    Media Relations
    571.306.3470
    [email protected]

    SOURCE Evolent Health

    Related Links

    http://www.evolenthealth.com

    Get the next $EVH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EVH

    DatePrice TargetRatingAnalyst
    1/10/2025$15.00Buy
    Needham
    12/3/2024$36.00 → $29.00Buy
    BTIG Research
    11/8/2024$38.00 → $16.00Overweight → Equal-Weight
    Stephens
    10/11/2024$35.00Overweight
    KeyBanc Capital Markets
    8/9/2024$28.00 → $33.00Hold → Buy
    Truist
    4/22/2024$40.00Buy
    Citigroup
    3/1/2024$45.00Outperform
    Oppenheimer
    1/3/2024$39.00Overweight
    Barclays
    More analyst ratings

    $EVH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Holder Diane bought $25,518 worth of shares (2,735 units at $9.33), increasing direct ownership by 4% to 70,584 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    3/10/25 8:20:54 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    PRESIDENT Mccarthy Daniel Joseph bought $99,470 worth of shares (11,040 units at $9.01), increasing direct ownership by 3% to 389,004 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    3/10/25 8:18:12 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Director Jelinek Richard M bought $273,750 worth of shares (30,000 units at $9.12) (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    3/10/25 8:16:20 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham initiated coverage on Evolent Health with a new price target

    Needham initiated coverage of Evolent Health with a rating of Buy and set a new price target of $15.00

    1/10/25 7:49:47 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    BTIG Research reiterated coverage on Evolent Health with a new price target

    BTIG Research reiterated coverage of Evolent Health with a rating of Buy and set a new price target of $29.00 from $36.00 previously

    12/3/24 7:52:53 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Evolent Health downgraded by Stephens with a new price target

    Stephens downgraded Evolent Health from Overweight to Equal-Weight and set a new price target of $16.00 from $38.00 previously

    11/8/24 7:50:07 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Evolent Announces Second Quarter 2025 Results

    WASHINGTON, Aug. 7, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended June 30, 2025. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "Evolent exceeded our EBITDA targets for the second quarter and raised our profitability outlook for the full year. In addition, we continue to see a rapidly accelerating pipeline for new business and based on this acceleration we would expect to exceed our historical growth rates fo

    8/7/25 4:10:00 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    NYSE Content Advisory: Pre-market update + Wall Street anticipates Fed's next move

    NEW YORK, July 29, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.  Ashley Mastronardi delivers the pre-market update on July 29th Stocks are fractionally higher Tuesday morning following another record close on Monday for the S&P 500, though the large-cap index only saw a slight gain during yesterday's session.More than 150 companies will report earnings this week. The week will be headlined by Microsoft, Meta, Amazon, and Apple, which will release quarterly figures and guidance in the coming days.The

    7/29/25 8:55:00 AM ET
    $EVH
    $ICE
    Other Consumer Services
    Consumer Discretionary
    Investment Bankers/Brokers/Service
    Finance

    Evolent To Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025

    Company to Participate in Upcoming Conferences WASHINGTON, July 14, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its second quarter 2025 financial results on Thursday, August 7, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com. Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "Evo

    7/14/25 8:00:00 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Evolent Health Inc

    SCHEDULE 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    8/14/25 3:07:26 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    SEC Form 10-Q filed by Evolent Health Inc

    10-Q - Evolent Health, Inc. (0001628908) (Filer)

    8/11/25 6:27:45 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Evolent Health Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Evolent Health, Inc. (0001628908) (Filer)

    8/7/25 4:15:43 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Shams Aammaad covered exercise/tax liability with 2,567 shares, decreasing direct ownership by 3% to 72,899 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    8/5/25 4:11:35 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Chief Executive Officer Blackley Seth was granted 67,150 shares, increasing direct ownership by 9% to 829,367 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    7/3/25 7:12:25 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    General Counsel Weinberg Jonathan was granted 23,394 shares, increasing direct ownership by 10% to 254,179 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    7/3/25 7:10:27 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Evolent Health Inc

    SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    11/12/24 9:55:15 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Evolent Health Inc

    SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    8/7/24 7:47:40 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Evolent Health Inc

    SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    7/10/24 10:10:34 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    Financials

    Live finance-specific insights

    View All

    Evolent Announces Second Quarter 2025 Results

    WASHINGTON, Aug. 7, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended June 30, 2025. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "Evolent exceeded our EBITDA targets for the second quarter and raised our profitability outlook for the full year. In addition, we continue to see a rapidly accelerating pipeline for new business and based on this acceleration we would expect to exceed our historical growth rates fo

    8/7/25 4:10:00 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Evolent To Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025

    Company to Participate in Upcoming Conferences WASHINGTON, July 14, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its second quarter 2025 financial results on Thursday, August 7, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com. Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "Evo

    7/14/25 8:00:00 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Evolent reiterates Q2 and full year guidance for Adjusted EBITDA

    Notes accelerating 2026 revenue bookings forecast Secures incremental non-dilutive financing WASHINGTON, June 20, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced that based on leading indicators and paid claims data through May, it continues to experience oncology cost trend below expectations coming into 2025. Evolent is reiterating its Q2 2025 Adjusted EBITDA guidance of $33M-$40M and its full year Adjusted EBITDA guidance of $135M-165M. John Johnson, Evolent's Chief Financial Officer, noted, "We are pleased to see oncology trend remaining below forecast now for the first two thi

    6/20/25 6:30:00 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $EVH
    Leadership Updates

    Live Leadership Updates

    View All

    Veradigm Announces Appointment of Two New Independent Directors and Transition of Board Leadership

    Appoints Jonathan Sacks and Bruce Felt to the Board Lou Silverman to Succeed Greg Garrison as Chairman Veradigm Inc. (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today its Board of Directors (the "Board") appointed two new independent directors, Jonathan Sacks and Bruce Felt, to the Board, effective March 19, 2025, and that Lou Silverman will succeed Greg Garrison as Chairman upon his retirement from the Board on that date. In addition, Mr. Felt will become the Chair of the Audit Committee of the Board upon Mr. Garrison's retirement. Further, independent director Vinit Asar has been named Chair of the Nominating and Go

    3/18/25 4:47:00 PM ET
    $CMBM
    $DOMO
    $EVH
    Radio And Television Broadcasting And Communications Equipment
    Technology
    Computer Software: Prepackaged Software
    Other Consumer Services

    Define Ventures Appoints Carolyn Magill as Venture Partner

    The former Aetion and Remedy Partners CEO joins Define to further drive innovation across provider, payer, and pharmaceutical sectors SAN FRANCISCO, March 11, 2025 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Carolyn Magill, former CEO of Aetion, has joined the firm as venture partner. Magill, leveraging her 25 years of invaluable experience scaling companies and fostering innovation within payer, provider, and pharmaceutical organizations, will partner with Define founders to scale their companies and become category-defining companies.

    3/11/25 5:30:00 AM ET
    $EVH
    $HIMS
    $LVGO
    Other Consumer Services
    Consumer Discretionary
    Medical/Nursing Services
    Health Care

    Evolent announces Dr. Von Nguyen as incoming Chief Medical Officer, effective January 1

    Longtime CMO Dr. Andrew Hertler to serve as senior advisor and CMO emeritus. WASHINGTON, Dec. 18, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, announced the appointment of Dr. Von Nguyen as Chief Medical Officer, effective January 1, 2025. Dr. Nguyen joined Evolent as Chief Clinical Officer in July 2024 after serving as clinical lead for population health at Google. Among other previous roles, he has been Chief Medical Officer at Blue Cross North Carolina, Deputy Associate Director of Policy and Strategy at the Centers for Disease Control and Prevention, and Senior Advisor at the Centers for Me

    12/18/24 4:10:00 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary